Firebrick Pharma (ASX:FRE) secured a AU$1.1 million investment from Pharma Nutria, part of the SV More Group of Companies, which includes its Philippine licensing partner, SV More Pharma, according to a Tuesday filing with the Australian bourse.
Pharma Nutria is acquiring 11.6 million shares in the company at AU$0.095 apiece, subject to a voluntary escrow of 12 months, the filing said.
Proceeds will be used to cover marketing expenses for Nasodine nasal spray in Singapore, new product development for all markets, and other operational working capital, according to the filing.
Firebrick Pharma shares rose nearly 9% in morning trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。